BI-690517 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-690517’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-690517 overview
BI-690517 is under development for the treatment of diabetic and non-diabetic chronic kidney disease. It is administered orally as a film coated tablet and also through intravenous route. The drug candidate was also under development for diabetic nephropathy. It acts by targeting aldosterone synthase enzyme.
For a complete picture of BI-690517’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.